IntegraGen specializes in researching and identifying genetic biomarkers, primarily in the field of oncology. The group offers high-speed genotyping services, medium-speed genotyping services, and ultra-high-speed sequencing services for academic research institutions and pharmaceutical groups. France accounts for 84.4% of net sales.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-29	€0.1860	0.00%	1
26-06-26	€0.1860	-0.53%	2,611
26-06-25	€0.1870	-0.53%	2,900
26-06-24	€0.1880	-1.83%	13,476
26-06-23	€0.1915	-0.26%	3,606

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Real-time Euronext Paris Other stock markets 03:00:22 2026-06-29 am EDT			5-day change	1st Jan Change
0.1860 ^EUR	0.00%		-3.12%	+39.85%

Jun. 16	IntegraGen Enters Receivership Proceedings
May. 28	IntegraGen to file for court-ordered receivership

Market Cap	881K 1M 812K 760K 1.42M 94.74M 1.45M 9.76M 3.77M 46.82M 3.77M 3.69M 162M	P/E 2019	-23x	P/E 2020	-36.6x
Enterprise Value	-2.23M -2.54M -2.05M -1.92M -3.61M -240M -3.68M -24.69M -9.55M -118M -9.54M -9.34M -411M	EV / Sales 2019	0.49x	EV / Sales 2020	1.17x
Free-Float	32.13%	Yield 2019 *	-	Yield 2020	-

Jun. 16	IntegraGen Enters Receivership Proceedings
May. 28	IntegraGen to file for court-ordered receivership
Apr. 24	SSH Communications Security, Intragen Enter European Data Sovereignty Partnership	MT
Apr. 23	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-10-30	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-02	IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025	CI
25-07-02	IntegraGen SA Reports Sales Results for the First Half of 2025	CI
25-04-29	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-15	IntegraGen SA Announces Unaudited Revenue Results for the Year 2024	CI
24-10-18	IntegraGen: losses reduced, share price soars
24-07-29	IntegraGen SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-18	IntegraGen Reports Sales Results for the First-Half of 2024	CI
24-04-30	IntegraGen SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

25-07-02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	PU
25-07-02	IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million	BU
25-04-29	IntegraGen: 2024 Annual Results	BU
25-01-15	IntegraGen : Inside Information / Information on annual revenues	PU
25-01-15	IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m	BU

IntegraGen Stock

Stocks

ALINT

FR0010908723

Biotechnology & Medical Research

Valuation: IntegraGen

Chart: IntegraGen

Latest news : IntegraGen

Press Releases: IntegraGen

News in other languages: IntegraGen

Quotes and Performance

Course Extremes

Managers and Directors: IntegraGen

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

Jun. 16	Bourse : tensions entre Unicredit et l'Allemagne, SpaceX flambe (encore), Bénéteau au régime
Jun. 16	IntegraGen en procédure de redressement judiciaire
Jun. 16	Le marché remet sa cape d'invincibilité
Jun. 16	IntegraGen convertit sa procédure de sauvegarde en redressement judiciaire
Jun. 15	IntegraGen annonce la conversion de sa procédure de sauvegarde en redressement judiciaire afin de poursuivre les discussions engagées avec des acteurs intéressés par ses activités

1 week	-3.12%
Current month	+3.33%
1 month	+3.33%
3 months	-7.46%
6 months	+36.76%
Current year	+39.85%

1 week	0.18	0.19
1 month	0.17	0.26
Current year	0.12	0.36
1 year	0.12	0.5
3 years	0.12	1.57
5 years	0.12	2.04
10 years	0.12	4.29

Manager	Title	Age	Since
Bernard Courtieu CEO	Chief Executive Officer	62	2009-11-08
Virginie de Coster DFI	Director of Finance/CFO	-	2022-12-31
Berengere Genin COO	Chief Operating Officer	-	2023-12-31

Director	Title	Age	Since
Bernard Courtieu CHM	Chairman	62	2011-09-21
Jean-Pol Detiffe BRD	Director/Board Member	53	2020-12-31
François Blondel BRD	Director/Board Member	62	2023-12-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTEGRAGEN	0.00%	-3.12%	-62.65%	-85.64%	1.4M
VERACYTE, INC.	+3.31%	+12.79%	+120.93%	+133.91%	4.83B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.51%	+19.57%	+77.78%	+205.54%	3.35B
BGI GENOMICS CO., LTD.	-4.54%	-2.42%	-29.51%	-42.93%	1.96B
IOVANCE BIOTHERAPEUTICS, INC.	+0.95%	+8.70%	+151.48%	-42.41%	1.9B
CAREDX, INC.	+3.48%	+10.08%	+49.87%	+228.62%	1.49B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+1.63%	+19.62%	+151.82%	-50.08%	917M
SEEGENE, INC.	-3.95%	+0.72%	-15.15%	+34.94%	842M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-1.09%	-7.70%	-38.35%	-20.12%	466M
CURIOX BIOSYSTEMS CO., LTD	-8.07%	-26.89%	-0.51%	-	435M
Average	-0.48%	+3.74%	+40.57%	+40.20%	1.62B
Weighted average by Cap.	+1.24%	+9.71%	+77.66%	+94.33%

	2019	2020
Net sales	8.28M 9.44M 7.63M 7.15M 13.4M 891M 13.68M 91.73M 35.5M 440M 35.46M 34.69M 1.53B	9M 10.26M 8.3M 7.77M 14.56M 968M 14.87M 99.71M 38.58M 479M 38.54M 37.7M 1.66B
Net income	-285K -325K -263K -246K -461K -30.65M -470K -3.16M -1.22M -15.15M -1.22M -1.19M -52.52M	-375K -428K -346K -324K -607K -40.35M -619K -4.15M -1.61M -19.94M -1.61M -1.57M -69.14M
Net Debt	-2.52M -2.87M -2.32M -2.17M -4.08M -271M -4.16M -27.9M -10.8M -134M -10.79M -10.55M -464M	-3.11M -3.55M -2.87M -2.68M -5.03M -334M -5.14M -34.44M -13.33M -165M -13.31M -13.02M -573M